NCT00738361View on ClinicalTrials.gov

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

July 31, 2012

Study Completion Date

April 30, 2013

Conditions

Intraocular Melanoma

Interventions

DRUG

nab-paclitaxel

150 mg/m2 weekly for 3 of 4 weeks every 28 days.

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Celgene Corporation

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER